The Cognivue Clarity® device is a self-administered, digital cognitive assessment that standardizes the patient’s experience and removes the bias that can exist with traditional testing methods. Cognivue’s proprietary technology collects over 130,000 data points and is highly sensitive to each individual patient. Using adaptive psychophysics, the test dynamically adapts as the patient moves through the test.
Assesses all cognitive domains with a highly sensitive 10-minute test that is supported by the science of adaptive psychophysics.
Calibrated the same across all devices, ensuring consistency and retest reliability while eliminating human error in administering and scoring the test.
Patient administered and reimbursable, producing one overall score that’s easy to understand and communicate, with clinically meaningful correlations within key cognitive domains.
Unlike cognitive testing done using paper and pencil tests, Cognivue® is based on neurophysiology and psychophysical research that dynamically tests cortical function.
Cognitive testing is often done using paper and pencil tests. These assessments are time-consuming, tedious, subject to tester bias and fatigue, and often too costly. Often, they are not administered at all unless specifically requested by a patient. A more recent trend has been digitalization of these paper and pencil tests to make them more accessible.
Cognivue changes all of this with a rapid and objective test that fits into the workflow of any busy doctor’s office. It produces a simple and easy to interpret one-page report with a single cognitive score. Something every patient can understand. Test results are also stored locally and cloud-based for longitudinal test comparison.
Below is a series of charts that compares Cognivue with traditional paper and pencil tests for cognitive function.
First computerized cognitive function testing solution cleared by FDA is self-administered by a patient in 10 minutes. A large-scale study conducted in 2014 compared Cognivue to standard neuropsychological tests, and led to the FDA clearance of the device.
The Alzheimer’s Disease Assessment Scale – Cognitive sub scale test evaluates cognitive impairment and can be administered by staff or a specialist (40 minutes).
.
These cognitive screening tools are administered by a Health Professional (20 minutes). The Montreal Cognitive Assessment (MoCA), Saint Louis Mental Status Examination (SLUMS), Mini-Mental State Examination (MMSE) and Modified Mini-Mental State (3MS) are traditional screening tests of cognitive abilities.
Psychogeriatric Assessment Scales test evaluates cognitive impairment and can be administered by a Clinical Interviewer (40 minutes).
General Practitioner assessment of Cognition (CPCOG) is a brief screening test for dementia normally performed in primary care setting. Six minute written test administered and scored by physician.
Cognivue Clarity is patient centric and science driven. It is based on adaptive psychophysics technology and over 15 years of research focusing on early detection of cognitive impairment. The technology is devised in a way that uniquely calibrates each individual’s motor and visual abilities and continuously adapts to the patient’s performance providing a customized test specifically for each patient.
The technology of psychophysics is the basis for our software algorithm. It quantitatively investigates how much of a stimulus we can detect and how we detect differences between stimuli in the environment using our sensory systems. It allows patients to identify and differentiate the correct stimulus from other incorrect stimuli and uses these responses to dynamically change the test to determine the patient’s thresholds (best achievable score) or failure point.
Early detection and proper management are key to overall cognitive health and quality of life.
Cognitive impairment may occur as a result of a variety of causes and manageable underlying conditions related to but not limited to cardiovascular and/or metabolic conditions, sleep disorders, hormonal imbalances, depression, chronic pain, post-concussion, post-stroke, multiple sclerosis, epilepsy, Parkinson’s disease, ADHD, autism, and neurological, focal, or chronic conditions as type-2 diabetes. Cognitive impairment may also be a result of long-term poor lifestyle choices such as substance abuse, sedentarism, and unhealthy diets.
Studies show that a healthy diet, exercise, occupational therapy and other lifestyle changes involving patients and caregivers may delay disease progression. The earlier the testing, the earlier the patient is diagnosed and can be managed appropriately.
Cognivue’s adaptive technology is protected by over 17 patents. It promotes consistency as each device is uniformly calibrated, so the clinician can compare scores regardless of the location the patient took the test in, eliminating human subjectivity/inaccuracy.
